Current status of bevacizumab in advanced ovarian cancer

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 889-899

  Tomao, Federica ^a   Papa, Anselmo ^a   Rossi, Luigi ^a   Caruso, Davide ^a   Panici, Pierluigi Benedetti ^a   Venezia, Martina ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Chemotherapy; Epithelial ovarian cancer; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; CA 125 ANTIGEN; CANFOSFAMIDE; CARBOPLATIN; DOXORUBICIN; ENDOSTATIN; EPOTHILONE B; FIBROBLAST GROWTH FACTOR; GIMATECAN; INTERLEUKIN 1; INTERLEUKIN 6; IRINOTECAN; IXABEPILONE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOSPONDIN; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG SAFETY; HUMAN; HYPERTENSION; OVARY CANCER; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; REVIEW; THROMBOEMBOLISM; TIME TO TREATMENT; TREATMENT DURATION;

EID: 84891074926     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S46301     Document Type: Review

References (98)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.
2. Fleming GF, Ronnet BM, Seidman J, Zaino RJ, Rubin SC. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, editors. Principles and Practice of Gynecologic Oncology, 5th ed. Philadelphia: Lippincot Williams and Wilkins; 2009:763-836.
3. Kusumbe AP, Bapat SA. Ovarian stem cell biology and the emergence of ovarian cancer stem cells. In: Bapat S, editor. Cancer Stem Cells: Identification and Targets. New York: John Wiley and Sons; 2008: 95-110.
4. Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002;8 Suppl 1:S22-S30.
5. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9(10): 1801-1805.
6. Pisano C, Bruni GS, Facchini G, Marchetti C, Pignata S. Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag. 2009;5(4): 421-426.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
8. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6.
9. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967-974.
10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
11. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9): 987-989.
12. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995;147(1):9-19.
13. Stone PJ, Goodheart MJ, Rose SL, et al. The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol. 2003;90(3): 566-571.
14. Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int J Gynecol Pathol. 2007;26(4):395-403.
15. Gadducci A, Ferrero A, Cosio S, et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res. 2006;26(5B):3925-3932.
16. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006;16(5):1789-1793.
17. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112(3):469-474.
18. Henriksen R, Gobl A, Wilander E, et al. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995;73(2):213-220.
19. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5): 1011-1027.
20. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol. 2011;121(1):230-238.
21. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007;25(20):2894-2901.
22. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005;54(6):369-377.
23. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology. 2006;119(2):254-264.
24. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795-803.
25. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579-591.
26. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005;8(2):169-182.
27. Chen H, Ye D, Xie X, Chen B, Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol. 2004;94(3):630-635.
28. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6): 735-745.
29. Osada R, Horiuchi A, Kikuchi N, et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol. 2006;37(11):1414-1425.
30. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29(17):2439-2442.
31. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer. 2009;100(1):1-7.
32. Bellati F, Napoletano C, Gasparri ML, et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol. 2012;83(1):35-46.
33. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother. 2004;53(3):176-186.
34. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005;174(1):215-222.
35. Lissoni P, Malugani F, Bonfanti A, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents. 2001;15(2): 140-144.
36. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024-1028.
37. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37(5): 363-369.
38. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193-3197.
39. Boss EA, Massuger LF, Thomas CM, et al. Vascular endothelial growth factor in ovarian cyst fluid. Cancer. 2001;91(2):371-377.
40. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80(1): 98-106.
41. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512-517.
42. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-1199.
43. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13(20):2025-2044.
44. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
45. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer. 2007;96(8):1159-1165.
46. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006;66(24):11520-11539.
47. McKeage MJ. Clinical trials of vascular disrupting agents in advanced non-small-cell lung cancer. Clin Lung Cancer. 2011;12(3):143-147.
48. Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011;22(9):2036-2041.
49. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
50. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17(4):771-776.
51. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010;28(1):154-159.
52. Rose PG, Drake R, Braly PS et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol. 2009; 27. Abstract 5546.
53. Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29(35):4662-4668.
54. Gonzalez-Martin A, Gladieff L, Tholander B et al. Safety of frontline bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. J Clin Oncol. 2012;30(Suppl). Abstract 5017.
55. Tillmanns TD, Lowe MP, Schwartzberg LS et al. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol. 2010;28(Suppl). Abstract 5009.
56. Horowitz NS, Penson RT, Duda DG, et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent Müllerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011;4(1):26-33.
57. Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483.
58. Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26): 2484-2496.
59. Korn EL, Freidlin B, Abrams JS. Bevacizumab in ovarian cancer. N Engl J Med. 2012;366(13):1256.
60. Burger RA. Bevacizumab in ovarian cancer. N Engl J Med. 2012; 366(13):1256-1257.
61. Copur MS, Obermiller AM, Ramaekers R. Bevacizumab in ovarian cancer. N Engl J Med. 2012 29; 366 (13): 1256-1257.
62. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol. 2010;28(19): 3101-3103.
63. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114(2):195-198.
64. Micha JP, Goldstein BH, Graham C, et al. Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology. 2006;71(1-2):49-53.
65. Micha JP, Goldstein BH, Mattison JA, et al. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer. Gynecol Oncol. 2005;96(1):132-135.
66. Lesnock JL, Farris C, Krivak TC, Smith KJ, Markman M. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 2011;122(3):473-478.
67. Mountzios G, Pentheroudakis G. Bevacizumab in ovarian cancer. N Engl J Med. 2012;366(13):1257.
68. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671-680.
69. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13(12):1225-1233.
70. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3): 1071-1121.
71. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
72. Herzog TJ, Vermorken JB, Pujade-Lauraine et al. Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study. Gynecol Oncol. 2011;122(2):350-355.
73. Rustin GJ, Vergote I, Eisenhauer E, et al; Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2): 419-423.
74. Randall LM, Sill MW, Burger RA, et al. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2012;124(3): 563-856.
75. Tomao F, Tomao S, Panici PB. Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view. J Clin Oncol. 2013;31(1):166-167.
76. Pujade-Lauraine E, Hilpert F, Weber B et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol. 2012; 30. Abstract LBA5002.
77. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23(9):1867-1874.
78. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007;97(12): 1618-1624.
79. Del Campo J, Roszak A, Ciuleanu T et al. Phase II open label randomized study of trabectedin given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. In: proceedings of the American Society of Clinical Oncology 2006 (42nd Annual Meeting of the American Society of Clinical Oncology); June 2-6, 2006, (Atlanta). Abstract 5031.
80. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107-3114.
81. Smit WM, Šufliarsky J, Werner TL, et al. A phase II study of patupilone (EPO906) in patients with platinum-resistant or platinum-refractory ovarian cancer. Clin Ovarian Other Gynecol Cancer. In press 2012.
82. Forster M, Kaye S, Oza A, et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res. 2007;13(14):4178-4184.
83. Colombo N, Kutarska E, Dimopoulos M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or-resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30(31):3841-3847.
84. De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-153.
85. Kavanagh JJ, Gershenson DM, Choi H, et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer. 2005;15(4):593-600.
86. Rose P, Edwards R, Finkler N, et al. Phase 3 study: canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd-line therapy of platinum (P)-resistant ovarian cancer (OC). J Clin Oncol. 2007;25. Abstract LBA5529.
87. Vergote I, Finkler N, del Campo J, et al. Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P)-refractory or resistant ovarian cancer (OC): phase 3 study results. J Clin Oncol. 2007;25. Abstract LBA5528.
88. Kavanagh JJ, Levenback CF, Ramirez PT, et al. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010;3:9.
89. Vergote I, Finkler NJ, Hall JB, et al. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2010;20(5):772-780.
90. Matulonis UA, Horowitz NS, Campos SM, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-5766.
91. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27(16):2686-2691.
92. Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer. 2009;45(8):1415-1423.
93. Sehouli J, Alvarez AM, Manouchehrpour S, et al. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol. 2012;124(2): 205-209.
94. Teneriello MG, Tseng PC, Crozier M, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2009;27(9):1426-1431.
95. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(1):111-115.
96. Tsubamoto H, Kawaguchi R, Ito K, et al. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330). Anticancer Res. 2013;33(3):1073-1079.
97. Pecorelli S, Ray-Coquard I, Tredan O, et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol. 2010;21(4):759-765.
98. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76-82